Compare TIVC & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIVC | ENVB |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.0M |
| IPO Year | 2021 | N/A |
| Metric | TIVC | ENVB |
|---|---|---|
| Price | $1.96 | $5.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 60.0K | ★ 1.9M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $4.55 |
| 52 Week High | $15.64 | $96.30 |
| Indicator | TIVC | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 49.01 |
| Support Level | $1.97 | $4.55 |
| Resistance Level | $2.70 | $13.25 |
| Average True Range (ATR) | 0.19 | 1.26 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 19.39 | 10.29 |
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.